It is encouraging to note an increased interest in inducing apoptosis in fusion-positive prostate cancer cells and disulfiram/sunitinib cotreatment induced apoptosis in TMPRSS2-ERG fusion-positive VCaP prostate cancer cells[108]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.